Background. Nebulized cyclosporine (CsA) has been shown to limit lung allog
raft rejection as well as intramuscular (IM) CsA, with limited blood diffus
ion. The present study determined the pharmacokinetic parameters of nebuliz
ed CsA, by the assessment of regional lung deposition and extrapulmonary di
ffusion of CsA.
Methods. CsA was given either by IM injection (10 mg/kg) or by aerosol (at
10 and 25 mg/kg doses); 70 rats were killed at 25 and 50 min, and at 2, 4,
6, 8, 12, 24, or 48 hr after CsA administration. CsA levels were measured i
n the whole lung, in central and peripheral parts of the lung, in whole blo
od, kidney, and heart, The areas under the concentration time curves (AUCs)
were determined.
Results. In blood, kidney, and heart, CsA levels were significantly higher
for IM than for aerosol administrations at 10 and 25 mg/kg doses. In the wh
ole lung, the AUC was greater for the aerosol route at 25 mg/kg doses (588
ng.hr/mg) than for the low-dose (200 ng.hr/mg) or IM administration (200 ng
.hr/mg). The central to peripheral index of CsA (ratio of AUC central/perip
heral part of the lung) was not significantly different for both aerosol ad
ministrations (0.63 and 0.69, respectively) and for the IM route (0.81).
Conclusions. Nebulized CsA allows better pulmonary concentration than IRI a
dministration, with equivalent central and peripheral deposition whatever t
he mode of administration, and results in lower levels in blood, kidney, an
d heart.